HealthTree Logo
search more_vert
App Logo
close
person Sign In / Create Account
Dr. Bensinger discusses a wide variety of new approaches to treatment including monoclonal antibody studies, new oral proteasome inhibitor studies, combinations with and without transplants, and the pros and cons of allo vs. auto transplantation
Dr. Bensinger discusses a wide variety of new approaches to treatment including monoclonal antibody studies, new oral proteasome inhibitor studies, combinations with and without transplants, and the pros and cons of allo vs. auto transplantation image
HealthTree Podcast for Multiple Myeloma
event Aug 30, 2013 / 11:00AM - 12:00PM MDT

Event Description

Dr. William I. Bensinger, MD, Fred Hutchinson Cancer Research Center, University of Washington Interview date: August 30, 2013 

On this week's show, Dr. William Bensinger reviews the many approaches at the Fred Hutchinson Cancer Research Center to both improve care and move towards a cure for myeloma.  He describes several early studies happening including the monoclonal antibody drug elotuzumab, which targets the CS1 protein and has had impressive results in combination with other therapies like lenalidomide and dex.  He describes several carfilzomib trials and how it is now being studied in combination with other therapies with and without autologous transplantation. He describes two new oral proteasome inhibitors -  oprozomib (an oral form of carfilzomib) and ixazomib (an oral form of bortezomib). He describes the potential for an anti-CD38 antibody as single agent to fight myeloma using daratumumab and other anti CD-38 approaches. He describes a new histone deacetylase inhibitor called ACY-1215, and describes how a new radioisotope called Yttrium-90 attached to a CD45 antibody is being used before allogeneic transplantation for patients with highly aggressive myeloma. He also discusses some of the pros and cons of allogeneic vs. autologous transplantation.  The live mPatient Radio podcast with Dr. Bensinger

Schedule & Agenda

person
Discussion
11:00AM
Dr William Bensinger & Jenny Ahlstrom

Speakers & Moderators

The panelist Jennifer Ahlstrom
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.

Read Bio

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.

support

Get In Touch With Us

phone

+1 800 709 1113

email

Support@healthtree.org

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Janssen Oncology
Adaptive Biotechnologies
Amgen Oncology
Abbvie
Genentech
Bristol Myers Squibb

Follow Us

facebook instagram twitter youtube